The Royal Pharmaceutical Society (RPS) has launched a learning programme to support pharmacists in identifying and managing patients with insomnia.
The programme, developed in collaboration with Idorsia Pharmaceuticals UK Ltd, will begin on October 15.
It will cover both acute and chronic insomnia, including its impact on co-morbidities such as mental health conditions and chronic pain.
The programme is designed for pharmacists working across primary and secondary care sectors.
It follows a blended learning approach and will include webinars, podcasts and e-learning modules to support and enrich learning.
RPS Head of Professional Development Helen Chang said, “We’re proud to collaborate with partners and experts like Idorsia to develop education that is high-quality, evidence-based and supports pharmacists directly in practice.
"Sleep health is a vital part of patient wellbeing, and pharmacists are in a key position to support those experiencing insomnia. This programme equips pharmacists with the skills and confidence to help meet this need.”
The insomnia learning programme forms part of the RPS’s 2025 education plan and aligns with wider NHS goals around improving sleep health.
Idorsia Pharmaceuticals has provided funding for this initiative and has reviewed and certified the materials in accordance with the ABPI Code of Practice.
